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The COVID-19 pandemic caused by the spread of SARS-
CoV-2 virus has already had a catastrophic impact with
more than 1.4 million deaths worldwide as of 29 November
2020 [1]. Many countries including the UK attempted to
control spread of the virus through nationwide lockdowns.
In the UK, “shielding” was implemented to protect those
deemed to be in high-risk groups including those over 75,
and those with haematological malignancies, including
myeloproliferative neoplasms (MPN). Haematological
malignancies have been associated with increased risk of
COVID-19-related death [2]. However, these disorders are
heterogeneous, and shielding is challenging for patients to
maintain for prolonged periods, particularly when dealing
with a poorly understood risk. While MPN patients are
known to have an increased risk of requiring hospital
admission with infections [3], the heterogeneity of this
population, combined with the limited knowledge of SARS-
CoV-2, means there is likely to be a spectrum of risk of
death from COVID-19 in MPN patients. With the imminent
threat of further waves of infection, or chronic low-level
population transmission, experience-based risk quantifica-
tion to inform clinical practice and patient information is
needed.
In order to provide further data on the consequences of
COVID-19 infection in patients with MPN, we conducted a
national survey coordinated by members of the National
Cancer Research Institute (NCRI) MPN subcommittee.
Members of the NCRI MPN subgroup coordinated data
collection on patients from their own centre and local
hospitals. Clinicians working in areas of the UK not well
represented by the MPN subgroup membership were also
contacted directly. Outcome data on thrombosis, bleeding,
and mortality were collected as well as information on
baseline characteristics, MPN treatment and infection
severity. The case report form, shown in Supplementary
Table 1, was distributed to centres and physicians had
discretion to select the most appropriate options from
dropdown menus. Data were fully anonymised locally and
collated within a central database. Analysis was conducted
using SPSS (IBM Corp., Armonk, NY). Categorical data
were compared using two-sided Χ2 or Fisher’s exact test and
continuous non-parametric data with Kruskall–Wallis test.
Survival analysis was performed using Kaplan–Meier esti-
mation with group comparison by log rank test for uni-
variable analysis and Cox proportional-hazard regression
was used for multivariable analysis. Age standardised
mortality rate was calculated using the 2013 European





Pk where Pk= standard population in
group k and mk= age-specific mortality rate in group k.
Haematologists at 42 hospitals were contacted. Replies
were received from 30 hospitals with 27 centres reporting
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one or more cases. In total, data were received on 77
patients with known MPN (essential thrombocythemia
(ET), n= 28, polycythemia vera (PV), n= 18, primary or
secondary myelofibrosis (MF), n= 27, and MPN unclassi-
fiable or MDS/MPN overlap syndrome, n= 4) with a
diagnosis of COVID-19 infection prior to 5 July 2020.
Patient demographics are presented in Table 1. Median
age was 74 years (IQR 63.5–82 years) and 45 (58%)
patients were male. Men were over-represented in our
cohort, potentially reflecting an increased susceptibility to
infection or severe infection (leading to reporting bias) with
COVID-19, especially for those with ET where male pre-
ponderance is not expected. The ISARIC study is a large,
prospective observational study of patients hospitalised with
COVID-19 [4]. Median age was 73 years and 57% were
male, similar to our MPN cohort, therefore as age and male
sex are known predictors of outcome from COVID-19,
ISARIC has been included in Table 1 for comparison [5].
ISARIC is not a perfect comparator however and contains a
smaller proportion of patients with hypertension and dia-
betes than our MPN cohort, which are also recognised
predictors of outcome from COVID-19 infection.
BMI was available in 45 (56%) patients and mean BMI
was 24.5 (95% CI 23.3–25.7). In addition to MPN, most
patients had at least one other significant co-morbidity
(median number was 1 (IQR 0–2)), while 20 (26%) patients
had no additional co-morbidities. The most frequent co-
morbidities were hypertension (n= 31, 40%), diabetes (n=
16, 21%), and cerebrovascular disease (n= 15, 19%). No
statistically significant differences were found in age, sex,
ethnicity, or co-morbidity between MPN subtypes.
The vast majority of patients were receiving active
treatment for their MPN with only seven (9%) patients
under watchful waiting. Patients not receiving cytoreductive
therapy are underrepresented in this cohort [6], possibly
reflecting a lower risk of developing severe COVID-19
infection, but this requires further investigation. Twenty-six
(34%) patients were on ruxolitinib, 38 (49%) on hydro-
xycarbamide, 4 (5%) on anagrelide, and 2 (3%) on inter-
feron. The indication for ruxolitinib was MF in 19 (73%) of
26 patients. Ruxolitinib treated MPN patients may be over-
represented in this cohort [7], therefore these patients could
have increased risk of developing symptomatic COVID-19
infection, although this remains speculative and requires
further exploration in independent studies. Antiplatelet
agents were being taken by 46 (60%) patients with 15
(20%) on full anticoagulation.
Infections were diagnosed between 11 March 2020 and
12 June 2020. Symptoms started a median of 4 days before
diagnosis (IQR 2–7 days) and were similar to previous
reports: 55 (71%) presenting with dyspnoea, 51 (66%)
cough, 46 (60%) fever, 10 (13%) diarrhoea, 9 (12%)
myalgia, and 3 (4%) nausea and vomiting.
COVID-19 infection was predominantly contracted in
the community (n= 55, 71%), but 22 (29%) had physician
reported hospital acquired infections. Infections peaked on
4 April 2020 in our cohort, similar to the UK peak on 5
April 2020 [8]. Hospital admission was required by 63
(82%) patients. Diagnosis was made by viral PCR test in 59
(77%) patients, imaging only in 8 (10%) and 6 (8%) were
diagnosed clinically (missing data in 4). WHO severity
score at presentation was Mild, Moderate, Severe or Critical
in 20 (26%), 19 (25%), 21 (27%), and 12 (16%) respec-
tively. Five patients had missing data. Of the 11 (14%)
patients requiring ICU admission, two (18%) received non-
invasive ventilation, nine (82%) intubation, and four (36%)
renal replacement therapy. Antibiotics were given to 54
(70%) patients but only three (4%) received azithromycin as
a treatment for COVID-19. No COVID-19 experimental
treatments or repurposed established treatments such as
dexamethasone were given. Treatment for MPN was con-
tinued in 39 (51%) patients and 32 (42%) stopped MPN
therapy, of whom nine stopped ruxolitinib.
Thrombosis occurred in four (5%) patients, two had a
pulmonary embolism and two an arterial thrombosis. Nei-
ther of the patients who developed a PE had a history of
venous thromboembolism (VTE) and were not taking
therapeutic anticoagulation (one was taking aspirin) prior to
admission. Both required enhanced respiratory support, one
CPAP and the other intubation during admission. One
patient developed a myocardial infarction whilst taking a
direct oral anticoagulant for atrial fibrillation and one an
ischaemic stroke whilst intubated in intensive care. Bleed-
ing occurred in three (4%) patients. All patients who had a
bleeding event were taking aspirin and two patients had
thrombocytopenia. Both patients with thrombocytopenia
were receiving cytoreductive treatment for ET.
At the time of data analysis 35 of 77 (45%) patients had
died, 40 (52%) had recovered, and 2 had ongoing illness.
The median follow-up for survivors was 74.5 days, and no
deaths occurred after 32 days. The overall survival for the
group at 32 days was 54% (Fig. 1A). Survival was sig-
nificantly different between those admitted to hospital and
those remaining in the community (45 vs 86% p= 0.02,
Fig. S1a). Age standardised mortality rate for MPN patients
who required hospitalisation with COVID-19 infection was
18,716 per 100,000 population (95% CI 12,330–25,102 per
100,000) and 14,058 deaths per 100,000 for the ISARIC
cohort (95% CI 13,846–14,271 per 100,000). COVID-19
was the primary cause of death in 33 (94%) and a con-
tributing factor in 1 (3%). One death was due to transfor-
mation to AML. Age over 65 years was associated with a
significantly worse overall survival (44 vs 80%, p= 0.005,
Fig. 1B), and while numbers are low, there were no deaths
in anyone under 50 (n= 5). COVID-19 disease severity at
presentation was also associated with a worse outcome
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Results of a national UK physician reported survey of COVID-19 infection in patients with a. . .
(survival by group, mild 100%, moderate 63%, severe 29%,
and critical 25%, p < 0.001, Fig. 1C). Unexpectedly, there
was no difference in survival by MPN type (54%, 56%,
56%, and 50% for ET, PV, MF, or other MPN, respectively,
p= 0.983, Fig. 1D). The effect of age remained an impor-
tant factor in all disease groups (Fig. 1E). The comparable
survival between MPN subgroups is surprising, as is the
high proportion of ET patients that required inpatient care
(96%). Although it is possible that this is reflective of an
increased susceptibility to COVID-19 infection in ET
patients, as recently reported by Wang et al. [9], this may
equally be accounted for by an uneven age distribution
between MPN subtypes and small sample size. After
adjustment for age, there was a non-significant trend for ET
patients to have a superior outcome (Fig. S1b), which
becomes more evident when COVID-19 severity is
accounted for (Fig. S1c).
There was no impact on survival by antiplatelet, antic-
oagulant (data not shown), or hydroxycarbamide use (55 vs
53%, p= 0.569, Fig. S1d). However, there was an age
dependent effect of ruxolitinib therapy on survival, with no
significant impact in those under 75 years (64 vs 68%, p=
0.727, Fig. S1e), but a significantly poorer outcome in those
over 75 years (11 vs 52%, p < 0.001, Fig. 1f). Patients
taking ruxolitinib at the onset of COVID-19 infection were
included in this analysis, including those that subsequently
stopped. There was no survival impact from discontinuing
ruxolitinib, but numbers were small.
Although observational data such as the current cohort
might be associated with certain biases, including the
potential selective reporting of more severe cases, we
believe that a number of important conclusions can be
drawn from these data. First, MPN patients admitted with
COVID-19 infection appear to have worse outcomes than
expected when compared to the ISARIC study, although
there are significant differences in baseline co-morbidities
(Table 1). Second, age is highly predictive of outcome.
Young MPN patients, particularly those undergoing





survival for entire MPN patient
cohort covering time from
COVID-19 diagnosis censored
at date of data submission (A).
Effect of age (B), COVID-19
severity on admission according
to WHO criteria (C), and MPN
subtype (D). Effect of age by
MPN subtype, each box
represents a patient, solid fill
box denotes survival and
hatched box death (E). Effect of
ruxolitinib treatment in patients
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observation only, were underrepresented in the cohort
suggesting that they either have milder infection or are less
susceptible to infection than older patients with MPN.
Therefore, younger MPN patients might not be at increased
risk compared to the general population, although it is
important to note that numbers included are small. How-
ever, older MPN patients may be at higher risk of death than
the age-matched population and therefore are more likely to
benefit from strict social distancing or shielding. Further-
more, comparison with a recently published large cohort of
chronic lymphocytic leukemia (CLL) shows similar out-
comes for MPN and CLL patients [10]. The outcome of
MPN patients in this study is worse than an Italian cohort of
haematological malignancy [11], where hospitalised MPN
patients with COVID-19 had a mortality rate of 33 vs 46%
in the current cohort. The reasons for this difference are
unclear although little granularity is available from the
Italian cohort for further comparison.
Data on thrombotic risk from COVID-19 infection are
highly variable, however a series of hospitalised patients
with a greater proportion of patients admitted to ICU found
rates of VTE at 5% and arterial thrombosis at 3% [12],
similar to our MPN cohort. This suggests that MPN patients
may not have an increased rate of thrombotic complications,
possibly due to the high proportion of patients on anti-
platelets or anticoagulation, but larger prospective studies
are required to confirm this.
The poor outcome of elderly patients pre-treated with
ruxolitinib is striking and ruxolitinib treated patients
account for one-third of the cohort, including 70% of MF
patients, more than would be expected based on real-world
UK data [7]. Although ruxolitinib is immunosuppressive, it
also has potential beneficial anti-inflammatory effects [13]
and has recently been proposed as a therapy for COVID-19
associated hyperinflammation and respiratory distress. It is
not possible to determine whether poor outcome in rux-
olitinib treated patients in our study is a direct result of the
drug, or whether ruxolitinib therapy is a surrogate of
severe MPN.
In summary, our data support that older MPN patients,
particularly those receiving ruxolitinib, might be at
increased risk of adverse outcomes following COVID-19
infection. Younger patients under observation may not be at
increased risk in comparison with the general population
and stringent shielding measures may not be required for
this patient group. It remains unknown how many patients
with MPN developed COVID-19 infection and it is very
likely many infections occurred in the community and were
not diagnosed, as early in the outbreak testing was mostly
limited to inpatients in the UK. Serology surveys of MPN
patients will be informative in this regard. Our study pro-
vides useful data to inform evidence-based risk stratification
of MPN patients with regards to risk of COVID-19
infection.
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